The co-stimulation of NKG2D with these bibodies enhanced CD19-DE-mediated ADCC against CD19+/CD20+ GRANTA-519 MCL target cells significantly and synergistically, even beyond the dose independent cytotoxicity plateau of single CD19-DE treatment (Figure 5, Table 1). This evidence concerns the gene CD19 and mantle cell lymphoma.